People: pSivida Corp (PSDV.W)

PSDV.W on CBOE When Trading NASDAQ Global Select Market

3.10USD
23 May 2013
Price Change (% chg)

$0.11 (+3.68%)
Prev Close
$2.99
Open
$3.06
Day's High
$3.10
Day's Low
$3.06
Volume
200
Avg. Vol
102
52-wk High
$3.10
52-wk Low
$1.23

Search Stocks

Summary

Name Age Since Current Position

David Mazzo

 55 2007 Independent Chairman of the Board

Paul Ashton

 51 2009 President, Chief Executive Officer, Director

Leonard Ross

 62 2009 Vice President - Finance, Principal Financial Officer

Lori Freedman

 45 2006 Vice President - Corporate Affairs, General Counsel, Company Secretary

Douglas Godshall

 48 2012 Independent Director

Paul Hopper

 2008 Independent Director

Michael Rogers

 53 2005 Independent Director

Peter Savas

 64 2008 Independent Director

Beverly Jedynak

 IR Contact Officer
» Insider Trading

Biographies

Name Description

David Mazzo

 Dr. David J. Mazzo, Ph.D., is Independent Chairman of the Board of pSivida Corp. Dr. Mazzo is President and Chief Executive Officer, and a director, of Regado Biosciences, Inc., a company pioneering the development of antithrombotic aptamers with active control agents, a position that he has held since August 2008. From April 2007 to April 2008, Dr. Mazzo served as the President and Chief Executive Officer, and as a director, of AEterna Zentaris, Inc., a biopharmaceutical company. From April 2003 to March 2007, Dr. Mazzo served as President and Chief Executive Officer, and a director of Chugai Pharma USA, the U.S. affiliate of Chugai, a Japanese pharmaceutical company and a member of the Roche Group. Dr. Mazzo previously held management positions in several international pharmaceutical companies, including serving as Senior Vice President, Global Development Operations at the Schering-Plough Research Institute and as Senior Vice President and Global Head Pharmaceutical Development at Hoechst Marion Roussel. Dr. Mazzo is also a director of AVANIR Pharmaceuticals.

Paul Ashton

 Dr. Paul Ashton is President, Chief Executive Officer, Director of pSivida Corp. Dr. Ashton was named President and Chief Executive Officer in January 2009 and previously served as Managing Director from January 2007 to January 2009 and Executive Director of Strategy from December 2005 to January 2007. From 1996 until its acquisition by pSivida in December 2005, Dr. Ashton was the President and Chief Executive Officer of Control Delivery Systems, Inc. (CDS), a drug delivery company that he co-founded in 1991 and that developed Durasert™ technology system. Dr. Ashton previously was a joint faculty member in the Departments of Ophthalmology and Surgery at the University of Kentucky, served on the faculty of Tufts University and worked as a pharmaceutical scientist at Hoffman-La-Roche.

Leonard Ross

 Mr. Leonard S. Ross is Vice President - Finance and Principal Financial Officer of pSivida Corp. From 2001 through April 2006, Mr. Ross served as Corporate Controller for NMT Medical, Inc., a medical device company. From 1990 to 1999, Mr. Ross was employed by JetForm Corporation, a developer of workflow software solutions, where he served in various capacities, including Vice President, Finance and Vice President, International Operations.

Lori Freedman

 Ms. Lori Freedman is Vice President - Corporate Affairs, General Counsel and Company Secretary of pSivida Corp. Prior to that, Ms. Freedman served as Vice President, Business Development, and Counsel of Macromedia, Inc., a provider of software for creating Internet content and business applications, from March 2001 through September 2001. Ms. Freedman has also served as Vice President, General Counsel, and Secretary of Allaire Corporation, a provider of Internet infrastructure for building business applications, from 1999 until Allaire’s acquisition by Macromedia in 2001, as Corporate Counsel of Polaroid Corporation from May 1998 to December 1998 and with the law firm of McDermott, Will & Emery.

Douglas Godshall

 Mr. Douglas Evan Godshall is Independent Director of pSivida Corp., since March 5, 2012. Mr. Godshall has been the Chief Executive Officer of HeartWare Limited and subsequently HeartWare International, Inc., since September 2006 and became a director of HeartWare Limited and subsequently HeartWare International, Inc., in October 2006. Prior to joining HeartWare Limited, Mr. Godshall served in various executive and managerial positions at Boston Scientific Corporation, where he had been employed since 1990, including as a member of Boston Scientific’s Operating Committee and since January 2005, as President, Vascular Surgery. Prior thereto, Mr. Godshall spent five years as Vice President, Business Development, at Boston Scientific, where he was focused on acquisition strategies for the cardiology, electrophysiology, neuroradiology and vascular surgery divisions. Mr. Godshall has a Bachelor of Arts in Business from Lafayette College and Masters of Business Administration from Northeastern University in Boston, Massachusetts.

Paul Hopper

 Mr. Paul A. Hopper is Independent Director of pSivida Corp. Mr. Hopper has served as managing director of Cappello Group, Inc., an investment bank, since November 2005, where he is head of the Life Science/Biotech Group and the Australia Desk. Mr. Hopper served as Executive Chairman of Cell Aquaculture Limited, an aquaculture company, from August 2007 to March 2008, as Executive Chairman of Bone Medical Limited, a drug delivery company, from July 2005 to July 2007 and as Managing Director of Australian Cancer Technology Limited, an oncology biotechnology company from September 2003 to February 2005. Mr. Hopper is also a director of Viralytics Limited and during the past 5 years was a director of Somnomed Limited and Fibrocell Science Inc. Mr. Hopper’s over 20 years of experience in international public company markets with sector experience including life sciences, biotechnology, financial services, nutraceuticals, specialty retail, mining, telecommunications, medical & healthcare services and e-commerce, and his focus on start-up and rapid growth companies, both in the U.S. and abroad, provide him with a global perspective on capital markets and financing, and his experience as a director of public companies gives him broad knowledge with respect to corporate governance issues.

Michael Rogers

 Mr. Michael W. Rogers is Independent Director of pSivida Corp. Since June 2009, Mr. Rogers has served as Executive Vice President and Chief Financial Officer of BG Medicine, Inc., a company focused on the development and commercialization of novel biomarker-based diagnostics. Mr. Rogers was Executive Vice President, Chief Financial Officer and Treasurer of Indevus Pharmaceuticals Inc., a specialty pharmaceutical company, from February 1999 until April 2009. Mr. Rogers was previously Executive Vice President and Chief Financial and Corporate Development Officer at Advanced Health Corporation, a health care information technology company, Vice President, Chief Financial Officer and Treasurer of AutoImmune, Inc., a biopharmaceutical company, and Vice President, Investment Banking at Lehman Brothers, Inc. and at PaineWebber, Inc. Mr. Rogers is also a director of Coronado Biosciences, Inc.

Peter Savas

 Mr. Peter G. Savas is Independent Director of pSivida Corp. Mr. Savas is Chairman and Chief Executive Officer of Alseres Pharmaceuticals, Inc., a company focused on the development of diagnostic and therapeutic products for disorders in the central nervous system, a position that he has held since September 2004. From September 2000 to March 2004, Mr. Savas served as Chief Executive Officer and President and, from April 2001 to March 2004, as Chairman, of Aderis Pharmaceuticals, Inc., a biopharmaceuticals company. From 1992 to 2000, Mr. Savas served as President of Unisyn, Inc., a contract manufacturer of biologics, and as Chief Executive Officer from 1995 to 2000. Mr. Savas is the Managing Partner of Tughill Partners, a life sciences consulting firm, and serves on advisory boards for Children’s Hospital Boston and Syracuse University.

Beverly Jedynak

Basic Compensation

Name Fiscal Year Total

David Mazzo

 91,955

Paul Ashton

 538,768

Leonard Ross

 370,590

Lori Freedman

 628,530

Douglas Godshall

 --

Paul Hopper

 --

Michael Rogers

 --

Peter Savas

 --

Beverly Jedynak

 --
As Of 29 Jun 2012

Options Compensation

Name Options Value

David Mazzo

 0 0

Paul Ashton

 0 0

Leonard Ross

 0 0

Lori Freedman

 0 0

Douglas Godshall

 0 0

Paul Hopper

 0 0

Michael Rogers

 0 0

Peter Savas

 0 0

Beverly Jedynak

 0 0

Insider Trading

Name Shares Traded Price

HOPPER PAUL EDWARD

 5,000 $1.68

HOPPER PAUL EDWARD

 5,000 $1.67
» Full list on Insider Trading
Search Stocks